Verena I Seliger1, David Rodman, Fredrick Van Goor, Andreas Schmelz, Peter Mueller. 1. Vertex Pharmaceuticals Incorporated, 130 Waverly Street, Cambridge, MA 02139-4242, USA; Faculty of Medicine, University of Ulm, Albert-Einstein-Allee 7, 89081 Ulm, Germany. Electronic address: verena_seliger@vrtx.com.
Abstract
BACKGROUND: Ivacaftor, a cystic fibrosis transmembrane regulator (CFTR) potentiator, decreased sweat chloride concentrations and improved clinical measures in cystic fibrosis (CF) patients with the G551D mutation. RESULTS: Sweat chloride measurements at day 15 had an overall positive predictive value (PPV) of 86.3%, a negative predictive value (NPV) of 65.5%, sensitivity of 73.9%, and specificity of 80.9% for an FEV1 improvement of ≥5% from baseline at week 16. For ivacaftor patients the median FEV1 improvement was 16.7%; for placebo patients 0.4%. For patients aged 6-11 years who received ivacaftor and who had a sweat chloride decrease of ≥40 mmol/L from baseline at day 15, a median weight gain of 11.2% at week 16, compared to 6% for those with a smaller decrease was observed. CONCLUSIONS: Changes in sweat chloride concentration at day 15 following treatment with ivacaftor may have sufficient predictive potential to identify individuals that show improvement in pulmonary function and weight gain after 16 weeks of treatment.
BACKGROUND:Ivacaftor, a cystic fibrosis transmembrane regulator (CFTR) potentiator, decreased sweat chloride concentrations and improved clinical measures in cystic fibrosis (CF) patients with the G551D mutation. RESULTS: Sweat chloride measurements at day 15 had an overall positive predictive value (PPV) of 86.3%, a negative predictive value (NPV) of 65.5%, sensitivity of 73.9%, and specificity of 80.9% for an FEV1 improvement of ≥5% from baseline at week 16. For ivacaftorpatients the median FEV1 improvement was 16.7%; for placebo patients 0.4%. For patients aged 6-11 years who received ivacaftor and who had a sweat chloride decrease of ≥40 mmol/L from baseline at day 15, a median weight gain of 11.2% at week 16, compared to 6% for those with a smaller decrease was observed. CONCLUSIONS: Changes in sweat chloride concentration at day 15 following treatment with ivacaftor may have sufficient predictive potential to identify individuals that show improvement in pulmonary function and weight gain after 16 weeks of treatment.
Authors: Meghan E McGarry; Beate Illek; Ngoc P Ly; Lorna Zlock; Sabrina Olshansky; Courtney Moreno; Walter E Finkbeiner; Dennis W Nielson Journal: Pediatr Pulmonol Date: 2017-01-09
Authors: Sonya L Heltshe; Nicole Mayer-Hamblett; Jane L Burns; Umer Khan; Arthur Baines; Bonnie W Ramsey; Steven M Rowe Journal: Clin Infect Dis Date: 2014-11-25 Impact factor: 9.079
Authors: Tayyab Rehman; Philip H Karp; Ping Tan; Brian J Goodell; Alejandro A Pezzulo; Andrew L Thurman; Ian M Thornell; Samantha L Durfey; Michael E Duffey; David A Stoltz; Edward F McKone; Pradeep K Singh; Michael J Welsh Journal: J Clin Invest Date: 2021-08-16 Impact factor: 19.456
Authors: Frank J Accurso; Fredrick Van Goor; Jiuhong Zha; Anne J Stone; Qunming Dong; Claudia L Ordonez; Steven M Rowe; John Paul Clancy; Michael W Konstan; Heather E Hoch; Sonya L Heltshe; Bonnie W Ramsey; Preston W Campbell; Melissa A Ashlock Journal: J Cyst Fibros Date: 2014-03 Impact factor: 5.527
Authors: Mahmoud H Abou Alaiwa; Jan L Launspach; Brenda Grogan; Suzanne Carter; Joseph Zabner; David A Stoltz; Pradeep K Singh; Edward F McKone; Michael J Welsh Journal: JCI Insight Date: 2018-08-09